Tickborne infections in the southern United States

American Journal of the Medical Sciences

Volumn 340, Issue 3, 2010, Pages 194-201

  Salinas, Linda J ^a,b,c,d   Greenfield, Ronald A ^a,b,c   Little, Susan E ^a,b,c   Voskuhl, Gene W ^a,b,c  

^a Infectious Diseases Section (111 C)   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c Baylor University   (United States)

^d Department of Medicine   (United States)

Author keywords

Ehrlichiosis; Rickettsia parkeri infection; Rocky mountain spotted fever; Tickborne infections; Tularemia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; EHRLICHIA VACCINE; GENTAMICIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RICKETTSIA VACCINE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TICK BORNE ENCEPHALITIS VACCINE; TULAREMIA VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANTIBIOTIC THERAPY; AVOIDANCE BEHAVIOR; BLOOD SAMPLING; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE TRANSMISSION; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EHRLICHIA CHAFFEENSIS; EHRLICHIOSIS; EPIDEMIOLOGICAL DATA; FEVER; HEADACHE; HUMAN; IMMUNIZATION; IMMUNOFLUORESCENCE; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY TEST; MENINGOENCEPHALITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICIAN; POLYMERASE CHAIN REACTION; PROGNOSIS; RASH; RICKETTSIA; RICKETTSIA PARKERI INFECTION; RICKETTSIOSIS; ROCKY MOUNTAIN SPOTTED FEVER; SEROLOGY; TICK; TICK BORNE DISEASE; TOOTH DISCOLORATION; TULAREMIA; UNITED STATES; TICK-BORNE DISEASES;

HUMANS; TICK-BORNE DISEASES; UNITED STATES;

EID: 77956886835     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e93817     Document Type: Conference Paper

References (85)

1. Felz MW, Durden LA. Identifying ticks: A pictorial guide. Patient Care 1998;32:172-187
2. Spielman A, Hodgson JC. The natural history of ticks: A human health perspective. In: Cunha BA, editor. Tickborne infectious diseases diagnosis and management. New York (NY): Marcel Dekker; 2000. p. 1-13.
3. Tickborne rickettsial diseases. Available at: Http://www.cdc.gov/ticks. Accessed February 24, 2010.
4. Ricketts H. The study of "Rocky Mountain spotted fever" (tick fever?) by means of animal inoculations. A preliminary communication. JAMA 1908;47:33-36
5. Wolbach S. Studies on Rocky Mountain spotted fever. J Med Res 1919;41:2-197.
6. Chen LF, Sexton DJ. What's new in Rocky Mountain spotted fever? Infect Dis Clin North Am 2008;22:415-432
7. Raoult D, Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 1997;10:694-719.
8. Roux V, Drancourt M, Raoult D. Determination of genome sizes of Rickettsia spp. within the spotted fever group, using pulsed-field gel electrophoresis. J Bacteriol 1992;174:7455-7457
9. Walker DH, Yu XJ. Progress in rickettsial genome analysis from pioneering of Rickettsia prowazekii to the recent Rickettsia typhi. Ann N Y Acad Sci 2005;1063:13-25.
10. Anacker RL, List RH, Mann RE, et al. Characterization of monoclonal antibodies protecting mice against Rickettsia rickettsii. J Infect Dis 1985;151:1052-1060
11. Crocquet-Valdes PA, Diaz-Montero CM, Feng HM, et al. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine 2001; 20:979-988
12. Walker DH. Targeting rickettsia. N Engl J Med 2006;354:1418-1420
13. Walker DH, Valbuena GA, Olano JP. Pathogenic mechanisms of diseases caused by Rickettsia. Ann N Y Acad Sci 2003;990:1-11.
14. Woods ME, Olano JP. Host defenses to Rickettsia rickettsii infection contribute to increased microvascular permeability in human cerebral endothelial cells. J Clin Immunol 2008;28:174-185
15. Walker DH, Ismail N. Emerging and re-emerging rickettsioses: Endothelial cell infection and early disease events. Nat Rev Microbiol 2008;6:375-386
16. Walker DH, Olano JP, Feng HM. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 2001;69:1841-1846
17. Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005;353:587-594
18. Burgdorfer W, Brinton LP. Mechanisms of transovarial infection of spotted fever Rickettsieae in ticks. Ann N Y Acad Sci 1975;266:61-72.
19. Azad AF, Beard CB. Rickettsial pathogens and their arthropod vectors. Emerg Infect Dis 1998;4:179-186
20. Salgo MP, Telzak EE, Currie B, et al. A focus of Rocky Mountain spotted fever within New York City. N Engl J Med 1988;318:1345-1348
21. Provisional cases of selected notifiable diseases. United States, week ending December 31, 2005. MMWR Morb Mortal Wkly Rep 2006;54: 1327.
22. Treadwell TA, Holman RC, Clarke MJ, et al. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg 2000;63:21-26
23. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: Epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995;52:405-413
24. Paddock CD, Holman RC, Krebs JW, et al. Assessing the magnitude of fatal Rocky Mountain spotted fever in the United States: Comparison of two national data sources. Am J Trop Med Hyg 2002;67:349-354
25. McQuiston JH, Holman RC, Groom AV, et al. Incidence of Rocky Mountain spotted fever among American Indians in Oklahoma. Public Health Rep 2000;115:469-475
26. Walker DH. Rocky Mountain spotted fever: A seasonal alert. Clin Infect Dis 1995;20:1111-1117
27. Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: Clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984;150:480-488
28. Maurin M, Raoult D. Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, 'Israeli spotted fever group rickettsia' and Coxiella burnetii. J Antimicrob Chemother 1997;39:725-730
29. Walker DH. The realities of biodefense vaccines against Rickettsia. Vaccine 2009;27 suppl 4:D52-5.
30. Parker RR, Kohls GM, Cox GW, et al. Observations on an infectious agent from Amblyomma maculatum. Public Health Rep 1939;54: 1482-1484
31. Paddock CD, Sumner JW, Comer JA, et al. Rickettsia parkeri: A newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis 2004;38:805-811
32. Paddock CD, Finley RW, Wright CS, et al. Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted fever. Clin Infect Dis 2008;47:1188-1196
33. Sumner JW, Durden LA, Goddard J, et al. Gulf Coast ticks (Amblyomma maculatum) and Rickettsia parkeri, United States. Emerg Infect Dis 2007;13:751-753
34. Cohen SB, Yabsley MJ, Garrison LE, et al. Rickettsia parkeri in Amblyomma americanum ticks, Tennessee and Georgia, USA. Emerg Infect Dis 2009;15:1471-1473
35. Maeda K, Markowitz N, Hawley RC, et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987;316:853-856
36. Paddock CD, Childs JE. Ehrlichia chaffeensis: A prototypical emerging pathogen. Clin Microbiol Rev 2003;16:37-64.
37. Dumler JS, Madigan JE, Pusterla N, et al. Ehrlichioses in humans: Epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 2007;45(suppl 1):S45-51.
38. Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999;341: 148-155
39. Walker DH, Dumler JS. Emergence of the ehrlichioses as human health problems. Emerg Infect Dis 1996;2:18-29.
40. Walker DH. Ehrlichia under our noses and no one notices. Arch Virol Suppl 2005;147-156
41. Paddock CD, Yabsley MJ. Ecological havoc, the rise of white-tailed deer, and the emergence of Amblyomma americanum-associated zoonoses in the United States. Curr Top Microbiol Immunol 2007;315: 289-324.
42. Wimberly MC, Baer AD, Yabsley MJ. Enhanced spatial models for predicting the geographic distributions of tick-borne pathogens. Int J Health Geogr 2008;7:15.
43. Dumler JS, Walker DH. Ehrlichia chaffeensis (human monocytotropic ehrlichiosis), Anaplasma phagocytophilum (human granulocytotropic ehrlichiosis), and other Anaplasmataceae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, Vol.2, 7th ed. Philadelphia (PA): Elsevier Churchill Livingstone; 2009. p. 2531-2537
44. Yabsley MJ. Natural history of Ehrlichia chaffeensis: Vertebrate hosts and tick vectors from the United States and evidence for endemic transmission in other countries. Vet Parasitol 2010;167:136-148
45. Davidson WR, Lockhart JM, Stallknecht DE, et al. Persistent Ehrlichia chaffeensis infection in white-tailed deer. J Wildl Dis 2001;37: 538-546
46. Chapman AS, Bakken JS, Folk SM, et al; Tickborne Rickettsial Diseases Working Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis-United States: A practical guide for physicians and other health-care and public health professions. MMWR Morb Mortal Wkly Rep 2006;55:1-27.
47. Liddell AM, Stockham SL, Scott MA, et al. Predominance of Ehrlichia ewingii in Missouri dogs. J Clin Microbiol 2003;41:4617-4622
48. Arens MQ, Liddell AM, Buening G, et al. Detection of Ehrlichia spp. in the blood of wild white-tailed deer in Missouri by PCR assay and serologic analysis. J Clin Microbiol 2003;41:1263-1265
49. Goodman RA, Hawkins EC, Olby NJ, et al. Molecular identification of Ehrlichia ewingii infection in dogs: 15 cases (1997-2001). J Am Vet Med Assoc 2003;222:1102-1107
50. Yabsley MJ, Varela AS, Tate CM, et al. Ehrlichia ewingii infection in white-tailed deer (Odocoileus virginianus). Emerg Infect Dis 2002; 8:668-671
51. Steiert JG, Gilfoy F. Infection rates of Amblyomma americanum and Dermacentor variabilis by Ehrlichia chaffeensis and Ehrlichia ewingii in southwest Missouri. Vector Borne Zoonotic Dis 2002;2:53-60.
52. Murphy GL, Ewing SA, Whitworth LC, et al. A molecular and serologic survey of Ehrlichia canis, E. chaffeensis, and E. ewingii in dogs and ticks from Oklahoma. Vet Parasitol 1998;79:325-339
53. Thomas RJ, Dumler JS, Carlyon JA. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther 2009;7:709-722
54. Standaert SM, Dawson JE, Schaffner W, et al. Ehrlichiosis in a golf-oriented retirement community. N Engl J Med 1995;333:420-425
55. Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci 2005;1063:361-373
56. Thomas DR, Sillis M, Coleman TJ, et al. Low rates of ehrlichiosis and Lyme borreliosis in English farmworkers. Epidemiol Infect 1998; 121:609-614
57. Ohashi N, Zhi N, Zhang Y, et al. Immunodominant major outer membrane proteins of Ehrlichia chaffeensis are encoded by a polymorphic multigene family. Infect Immun 1998;66:132-139
58. Nandi B, Hogle K, Vitko N, et al. CD4 T-cell epitopes associated with protective immunity induced following vaccination of mice with an ehrlichial variable outer membrane protein. Infect Immun 2007;75: 5453-5459
59. Loftis AD, Reeves WK, Spurlock JP, et al. Infection of a goat with a tick-transmitted Ehrlichia from Georgia, U.S.A., that is closely related to Ehrlichia ruminantium. J Vector Ecol 2006;31:213-223
60. Yabsley MJ, Loftis AD, Little SE. Natural and experimental infection of white-tailed deer (Odocoileus virginianus) from the United States with an Ehrlichia sp. closely related to Ehrlichia ruminantium. J Wildl Dis 2008;44:381-387
61. Reeves WK, Loftis AD, Nicholson WL, et al. The first report of human illness associated with the Panola mountain Ehrlichia species: A case report. J Med Case Reports 2008;2:139.
62. Dawson JE, Warner CK, Baker V, et al. Ehrlichia-like 16S rDNA sequence from wild white-tailed deer (Odocoileus virginianus). J Parasitol 1996;82:52-58
63. McCoy GW, Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent, Bacterium tularense. J Infect Dis 1912;10:61-72.
64. Wherry WB, Lamb BH. Infection of man with Bacterium tularense. J Infect Dis 1914;15:331-340
65. Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002;8:225-230
66. Pechous RD, McCarthy TR, Zahrt TC. Working toward the future: Insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev 2009;73:684-711.
67. Karlsson J, Prior RG, Williams K, et al. Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine. Microb Comp Genomics 2000;5:25-39.
68. Tularemia. United States, 1990-2000. MMWR Morb Mortal Wkly Rep 2002;51:181-184
69. Nigrovic LE, Wingerter SL. Tularemia. Infect Dis Clin North Am 2008;22:489-504, ix.
70. O'Toole D, Williams ES, Woods LW, et al. Tularemia in range sheep: An overlooked syndrome? J Vet Diagn Invest 2008;20:508-513
71. Machado LJ, Carabin H, Akins DR. Tularemia. In: Bronze MS, Greenfield RA, editors. Biodefense: Principles and pathogens. Norfolk (England): Horizon Bioscience; 2005. p. 313-337
72. Boyce JM. Recent trends in the epidemiology of tularemia in the United States. J Infect Dis 1975;131:197-199
73. Evans ME, Gregory DW, Schaffner W, et al. Tularemia: A 30-year experience with 88 cases. Medicine (Baltimore) 1985;64:251-269
74. McCrumb FR. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev 1961;25:262-267
75. Feldman KA, Enscore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 2001;345: 1601-1606
76. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 1989;11:440-451
77. Tarnvik A, Berglund L. Tularaemia. Eur Respir J 2003;21:361-373
78. Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: Two cases and review. Clin Infect Dis 1999;29:922-924
79. Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008;52:2276-2278
80. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: Medical and public health management. JAMA 2001;285:2763-2773
81. Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 2002;323:299-315.
82. Saslaw S, Eigelsbach HT, Wilson HE, et al. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med 1961;107:689-701.
83. Saslaw S, Eigelsbach HT, Prior JA, et al. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 1961;107:702-714
84. Willadsen P. Anti-tick vaccines. Parasitology 2004;129(suppl):S367-87.
85. Maritz-Olivier C, Stutzer C, Jongejan F, et al. Tick anti-hemostatics: Targets for future vaccines and therapeutics. Trends Parasitol 2007;23: 397-407.